Skip to Content

New Drug Approvals Archive - June 2014

See also: New Indications and Dosage Forms for June 2014

June 2014

Vogelxo (testosterone) Transdermal Gel

Date of Approval: June 4, 2014
Company: Upsher-Smith Laboratories, Inc.
Treatment for: Hypogonadism -- Male

Vogelxo (testosterone) transdermal gel is an androgen indicated for testosterone replacement therapy in males with hypogonadism.

Eloctate (antihemophilic factor (recombinant)) for Injection

Date of Approval: June 6, 2014
Company: Biogen Idec, Inc.
Treatment for: Hemophilia A

Eloctate (antihemophilic factor (recombinant) Fc Fusion Protein is a recombinant DNA derived, antihemophilic factor indicated for the treatment of patients with Hemophilia A.

Jublia (efinaconazole) Topical Solution

Date of Approval: June 6, 2014
Company: Valeant Pharmaceuticals International, Inc.
Treatment for: Onychomycosis -- Toenail

Jublia (efinaconazole) is a topical triazole antifungal for the treatment of onychomycosis of the toenails.

Bunavail (buprenorphine and naloxone) Buccal Film

Date of Approval: June 6, 2014
Company: BioDelivery Sciences International, Inc.
Treatment for: Opiate Dependence

Bunavail (buprenorphine and naloxone) buccal film is an opioid analgesic/opioid antagonist formulation for the maintenance treatment of opioid dependence.

Sivextro (tedizolid phosphate) Tablets and Injection

Date of Approval: June 20, 2014
Company: Cubist Pharmaceuticals, Inc.
Treatment for: Skin and Structure Infection

Sivextro (tedizolid phosphate) is an oxazolidinone antibiotic drug indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Afrezza (insulin human [rDNA origin]) Inhalation Powder - formerly Afresa

Date of Approval: June 27, 2014
Company: MannKind Corporation
Treatment for: Diabetes Type 1, Diabetes Type 2

Afrezza (insulin human [rDNA origin]) is a rapid acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.

Vazculep (phenylephrine hydrochloride) Injection

Date of Approval: June 27, 2014
Company: Flamel Technologies
Treatment for: Hypotension

Vazculep (phenylephrine hydrochloride) injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of hypotension resulting primarily from vasodilation in the setting of anesthesia.

New Drug Approvals Archive

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.